Rapid AMI assay
This article was originally published in The Gray Sheet
Executive Summary
Bayer Diagnostics will market and distribute a rapid point-of-care immunoassay system that the firm will develop with Siemens Medical Solutions and German firm peS Gesellschaft für medizinische Diagnosesysteme mbH, Bayer announces Sept. 7. The first assay developed on the system will screen for acute myocardial infarction using a small amount of whole blood, but "various pathological conditions" will eventually be added...